Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
March 2, 2018 – XYMOGEN, Inc., a leading manufacturer of medical foods and dietary supplements, announced today that is has prevailed in a lawsuit with Thorne Research. On February 20, 2018, after a six-day trial, a jury in the United States District Court for the District of Utah ruled for XYMOGEN. The jury found that XYMOGEN’s proprietary and highly-absorbed CoQMax product was actually invented by a chemist from XYMOGEN’s manufacturer thereby invalidating Thorne’s patent on their product.
|
|||
“I am extremely pleased that the jury saw fit to discredit Thorne’s claims and invalidate their patent”, said Brian Blackburn, XYMOGEN’s Founder and CEO. “Claiming a patent on an invention by a third-party misleads the public, and I hope the jury’s verdict will deter others from similar practices.”
About XYMOGEN:
To learn more about XYMOGEN, a family-owned, health sciences company, and its formulas, distribution, and community involvement, visit XYMOGEN.com, email [email protected], or call 800-647-6100. XYMOPrint, a full-service digital printer and design studio, XYMOGEN LOGISTICS, a third-party fulfillment, warehousing, and shipping provider; and PharmaceutiX Medical Foods are all subsidiaries of XYMOGEN.
6900 Kingesporte Parkway
Orlando, Fl
Tel: 800-647-6100
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a48371c-6283-4c53-afa1-bb7a889b35d1
Meghan Blackburn XYMOGEN 800-647-6100, Ext. 8875 [email protected]
